RxDoctor Payments Data

John Forrest, MD

Cardiovascular Disease · New Haven, CTNPI 1386827491

Payments from drug & device makers

What this record shows

The money is spread across several categories — speaking fees (35.9%), travel and lodging and consulting fees — rather than concentrated in one kind of arrangement. Medtronic accounts for 82.5% of it on its own, with 10 other manufacturers making up the rest. Among cardiovascular disease clinicians in CT with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$164,002in general payments, 2019–2025

Across 576 payments — averaging $284.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$135K
  • Edwards Lifesciences$12K
  • Boston Scientific$12K
  • Abbott$2K
  • Ancora Heart, Inc.$994
  • Merit Medical Systems Inc$400
  • plus $460 from 5 others
$1,001,897in research payments, 2019–2025

Across 321 payments — averaging $3121.17 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Medtronic$610K
  • Edwards Lifesciences$277K
  • Abbott$111K
  • Boston Scientific$4K

What the payments were for

  • Consulting fees$33,47020%
  • Speaking & faculty fees$58,83236%
  • Travel & lodging$52,23632%
  • Food & beverage$19,24012%
  • Education$2250%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$164,002 in reported general payments places this provider in the 95th percentile of 415 cardiovascular disease providers in Connecticut.

See all cardiovascular disease providers in Connecticut

Medicare billing

Part B allowed, 2024
$131,753
Medicare patients
242
Services billed
568

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Furosemide15$71

Paid to pharmacies, not to this prescriber.

Other cardiovascular disease in New Haven

See the full list for Connecticut

Where these figures come from

Is this you, or does something look wrong? →